David Quinn

22PUBLICATIONS
188CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Mar 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

John O Mascarenhas, Laura Maria Fogliatto, Steven D Green

|Jul 02, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Andrea B Apolo, Daniel M Girardi, Scot A Niglio

|Sep 11, 2023
SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.

Xinyi Zhou, Yohei Sekino, Hong-Tao Li

|Apr 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.

Emmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka

|Mar 17, 2023
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.

H Josh Jang, Galen Hostetter, Alexander W Macfarlane

Pageof 4

Frequent Collaborators

4 joint publications

Nicholas Vogelzang

3 joint publications

Elizabeth R Plimack

3 joint publications

Primo N Lara

3 joint publications

Neeraj Agarwal